Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients

Renal Failure

Volumn 32, Issue 8, 2010, Pages 903-912

  Yilmaz, Rahmi ^a   Altun, Bulent ^a   Kahraman, Serkan ^a   Ozer, Necla ^a   Akinci, Devrim ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Atherosclerosis; Cardiovascular; Hemodialysis; Hypertension; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; RAMIPRIL;

ADULT; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; CAROTID ARTERIES; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RAMIPRIL; RENAL DIALYSIS; STROKE VOLUME; TUNICA INTIMA; TUNICA MEDIA;

EID: 77955950009     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.502276     Document Type: Article

References (32)

1. Hörl MP, Hörl WH. Hemodialysis-associated hypertension: Pathophysiology a therapy. Am J Kidney Dis. 2002;39:227-244.
2. Degoulet P, Legrain M, Réach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Nephron 1982;31: 103-110.
3. Huysmans K, Lins RL, Daelemans R, et al. Hypertension and accelerated atherosclerosis in ESRD. J Nephrol. 1998;11(4): 185-195.
4. Lin YP, Chen CH, Yu WC, et al. Left ventricular mass and hemodynamic overload in normotensive hemodialysis patients. Kidney Int. 2002;62:1828-1838.
5. Sehridan D. Regression of left ventricular hypertrophy: Do antihypertensive classes differ? J Hypertens. 2000;18:21-27.
6. Stanton AV, Chapman JN, Mayet J, et al. Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Clinical Sci. 2001;101:455-464.
7. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
8. Kawagishi T, Nishizawa Y, Konishi T, et al. High resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int. 1995;48:820-826.
9. Pascazio L, Bianco F, Giorgini A, et al. Echo color Doppler imaging of carotid vessels in hemodialysis patients: Evidence of high levels of atherosclerotic lesions. Am J Kidney Dis. 2002;28:713-720.
10. Weidmann P, Maxwell MH, Lupu AN, et al. Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med. 1971;285:757-762.
11. Wang AY, Li PK, Lui SF, Sanderson JE. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: What is the evidence? Nephrology (Carlton). 2004;9:190-197.
12. Foley RN, Parfrey PS, Harnett JD, et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024-2031.
13. Cannella G, Paoletti E, Delfino R, et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int. 1993; 44:881-886.
14. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.
15. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340-349.
16. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25:871-878.
17. Tan LB, Brilla C, Weber KT. Prevention of structural changes in the heart in hypertension by angiotensin converting enzyme inhibition. J Hypertens. 1992;10(Suppl. 1):31-34.
18. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
19. Wang AY, Li PK, Lui S, Sanderson JE. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: What is the evidence? Nephrology 2004;9:190-197.
20. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994;90(6):2786-2796.
21. Paoletti E, Cassottana P, Bellino D, et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis. 2002;40(4):728-736.
22. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328.
23. Yu WC, Lin YP, Lin IF, et al. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis. 2006;47(3):478-484.
24. Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist losartan causes regression of left ventricular hypertrophy in end stage renal disease. Nephron 2002;90:256-261.
25. London GM, Marchais SJ, Safar ME, et al. Aortic and large artery compliance in end-stage renal failure. Kidney Int. 1990;37:137-142.
26. Blacher J, Guerin AP, Pannier B. et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
27. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-992.
28. London GM, Guerin AP, Pannier B, et al. Large artery structure and function in hypertension and end stage renal disease. J Hypertens. 1998;16:1931-1938.
29. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-Up Program. The Hypertension Detection and Follow-Up Program Cooperative Group. Hypertension 1989;13(Suppl. 5):80-93.
30. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: A meta-analysis of randomized controlled trials. Stroke 2006;37:1933-1940.
31. Kakinuma Y, Kawamura T, Bills T, et al. Blood pressureindependent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992;42(1):46-55.
32. Törnig J, Amann K, Ritz E, et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: The effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol. 1996;7(5):667-675.